Chloroquine was shown in 2004 to be active in vitro against SARS coronavirus but is of unproven efficacy and safety in patients infected with SARS-CoV-2. The drug’s potential benefits and risks for COVID-19 patients, without and with azithromycin, is discussed by Dr. David Juurlink, head of the Division of Clinical Pharmacology and Toxicology at Sunnybrook Health Sciences Centre in Toronto.
 logo final copy.png)
The Hippocratic Editorial and VT team. Please send your suggestions to submissions@hippocraticpost.com
Latest posts by Hippocratic Post (see all)
- Late miscarriage may increase future pregnancy risk - 27th February 2026
- Leadless pacemakers to treat thousands with slow heart rhythms - 27th February 2026
- Vegetarian diet lowers risk of five cancers - 27th February 2026
